(NASDAQ: GPCR) Structure Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.18%.
Structure Therapeutics's earnings in 2026 is -$170,337,000.On average, 19 Wall Street analysts forecast GPCR's earnings for 2026 to be -$357,426,635, with the lowest GPCR earnings forecast at -$424,186,928, and the highest GPCR earnings forecast at -$296,423,378. On average, 17 Wall Street analysts forecast GPCR's earnings for 2027 to be -$448,984,827, with the lowest GPCR earnings forecast at -$524,487,286, and the highest GPCR earnings forecast at -$373,887,493.
In 2028, GPCR is forecast to generate -$506,747,087 in earnings, with the lowest earnings forecast at -$668,669,050 and the highest earnings forecast at -$324,632,853.